Related Experiment Videos
Ifosfamide and cyclophosphamide: effects on immunosurveillance
G Binotto1, L Trentin, G Semenzato
1Padua University School of Medicine, Department of Clinical and Experimental Medicine, Clinical Immunology Branch, Padua, Italy.
Oncology
|October 31, 2003
Summary
Ifosfamide (IF) and cyclophosphamide (CTX) are chemotherapy drugs with dual antitumor actions. They can be combined with immunotherapy, with CTX enhancing cellular immune response and IF inhibiting lymphocyte proliferation.
Area of Science:
- Oncology
- Immunology
- Pharmacology
Background:
- Ifosfamide (IF) and cyclophosphamide (CTX) are chemotherapy agents used for human malignancies.
- These drugs possess a bimodal mechanism of action, including cytotoxic and immunomodulatory effects.
- Their effects are particularly relevant when combined with adoptive immunotherapy.
Purpose of the Study:
- To investigate the combined effects of IF and CTX on antitumor action.
- To elucidate the immunomodulatory mechanisms of IF and CTX in the context of immunotherapy.
- To determine the potential for combining IF and CTX based on tumor immunogenicity.
Main Methods:
- Analysis of the effects of IF on human peripheral blood lymphocytes' proliferative response to interleukin-2.
- Assessment of IF-induced phosphorylation of HSP27 via glutathione depletion.
- Evaluation of CTX's impact on cytokine profiles and Th1 cell expansion.
Main Results:
- IF irreversibly inhibits interleukin-2-driven lymphocyte proliferation in a dose-dependent manner.
- IF may induce HSP27 phosphorylation by depleting glutathione.
- CTX promotes cytokine profiles that upregulate Th1 cell expansion, potentially enhancing cellular immunity.
Conclusions:
- Treatment regimens combining CTX and IF show potential for cancer therapy.
- The efficacy of CTX and IF combination therapy may be modulated by tumor immunogenicity.
- These findings support the strategic use of IF and CTX in conjunction with immunotherapy.